Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes
Apoptosis · 2026
DOI: 10.1007/s10495-026-02446-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, 2026. Verfasst von Yue Lv und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150000, Heilongjiang, China. Hauptthemen laut MEDLINE: Lysosomal-Associated Membrane Protein 2, Urinary Bladder Neoplasms, Membrane Proteins, Deoxycytidine. Die Arbeit nennt 42 Literaturangaben. Gefördert von: the China Primary Healthcare Foundation.
Abstract (Originalsprache)
Bladder cancer (BLCA) is an aggressive malignancy characterized by metastasis and drug resistance, creating an urgent demand for novel therapeutic targets. The lysosomal protein LAMP2 acts as a key oncogenic driver in BLCA and modulates the degradation of STING. As reported in prior studies, mechanistically, p62-mediated macroautophagy and HSC70-dependent chaperone-mediated autophagy (CMA) facilitate STING degradation. LAMP2 increases STING ubiquitination, leading to its lysosomal degradation in BLCA. Moreover, LAMP2 knockdown suppresses BLCA cell proliferation and migration. In our experimental systems, it also induces M1-type tumor-associated macrophages (TAMs) polarization and reduces TAM infiltration. RNF5 and TRIM56 are known to mediate K48/K63-linked ubiquitination of STING. Here, we demonstrate LAMP2 modulates this ubiquitination pattern in BLCA. Via virtual screening, we discover MRGPRX4 modulator-2 (Mm-2), a LAMP2-binding small molecule with anti-tumor activity against BLCA. Combined with gemcitabine (GEM), Mm-2 blocks autophagic flux and activates STING signaling. It also alters TAM phenotypes in our in vitro and in vivo models. The LAMP2-STING-TAMs axis shows potential as a therapeutic target for modulating the tumor immune microenvironment (TME) and affecting drug response in BLCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150000, Heilongjiang, China.
- Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Heilongjiang, China.
- Department of Ultrasound Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150000, Heilongjiang, China. ganxiuguo@qq.com.
- Department of Pathology, Ping Xiang People's Hospital, Pingxiang Economic and Technological Development District, No. 8, Wugong Mountain Avenue, Development Zone, Ping Xiang, 337000, Jiangxi, China. jiangxiren111@126.co…
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150000, Heilongjiang, China. Liuzan@hrbmu.edu.cn.
Förderung
- the China Primary Healthcare Foundation
Zitieren
APA
Lv, Y., Yin, Q., Li, W., Deng, L., Liu, J., Lv, H., Zhang, P., Qiu, Y., Guo, D., Tao, R., Gan, X., Xu, F., Liu, Z., & Wang, Y. (2026). Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes. Apoptosis. https://doi.org/10.1007/s10495-026-02446-4
Vancouver
Lv Y, Yin Q, Li W, Deng L, Liu J, Lv H, et al. Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes. Apoptosis. 2026. doi:10.1007/s10495-026-02446-4
BibTeX
@article{Lv2026,
author = {Lv, Yue and Yin, Qiang and Li, Wuheng and Deng, Leihong and Liu, Jiasheng and Lv, Haolong and Zhang, Peng and Qiu, Yihang and Guo, Difeng and Tao, Rui and Gan, Xiuguo and Xu, Fanghua and Liu, Zan and Wang, Yongquan},
title = {Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes},
journal = {Apoptosis},
year = {2026},
doi = {10.1007/s10495-026-02446-4}
}
EUVIMED